A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine
Clinical Trial Grant
Administered By
Neurology, Headache and Pain
Awarded By
Alder BioPharmaceuticals, Inc.
Start Date
January 27, 2017
End Date
December 31, 2018
Administered By
Neurology, Headache and Pain
Awarded By
Alder BioPharmaceuticals, Inc.
Start Date
January 27, 2017
End Date
December 31, 2018